Dogs that have oral squamous cell carcinomas often need surgery that disfigures their jaws and lower their quality of ...

Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with ...

RTKs can activate Ras, a protein that is tethered to the plasma membrane, by causing it to bind GTP. Once activated, Ras can do a variety of things. In this example, it activates an enzymatic ...

Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support ...

Dogs that have oral squamous cell carcinomas often need surgeries that disfigure their jaws and lower their quality of life - and in 20% of dogs ...

Consequently, new therapeutic strategies are required. Pippa Newell and colleagues found that molecular alterations of the Ras pathway are common in HCC and that the multikinase inhibitor ...

The laboratory is studying small molecules that selectively inhibit the components of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. These compounds are being used as reagents to define the role of these ...

It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused ...

Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with ...